Racial Disparity in Response to Prostate Cancer Systemic Therapies.
PURPOSE OF REVIEW: In this review, we aim to describe racial differences in response to treatment for metastatic castration-resistant prostate cancer (mCRPC). RECENT FINDINGS: Recent data suggests that, despite higher risk features, African Americans may respond better than Caucasians to systemic therapies for advanced prostate cancer. This improved response is not limited to one class of drugs but can be seen with androgen-pathway directed therapies, chemotherapy, bone-targeted therapy, and immunotherapy. The mechanisms for this are being further explored. African Americans may respond better to mCRPC treatments but validation in prospective clinical trials is needed.
Bitting, RL; Goodman, M; George, DJ
Volume / Issue
Start / End Page
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)